[Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin].
Tamura
K
K
Molecular Biological Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
D000818:Animals; D001921:Brain / Q000502:physiology; D019703:Calcineurin / Q000502:physiology; D065095:Calcineurin Inhibitors; D015220:Calcium Channels / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000502:physiology; D018149:Glucose Intolerance / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D050778:NFATC Transcription Factors; D009474:Neurons / Q000473:pathology; D009687:Nuclear Proteins; D015398:Signal Transduction / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology*; D014157:Transcription Factors / Q000502:physiology
D065095:Calcineurin Inhibitors; D015220:Calcium Channels; D016207:Cytokines; D004268:DNA-Binding Proteins; D007166:Immunosuppressive Agents; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D014157:Transcription Factors; D016572:Cyclosporine; D019703:Calcineurin; D016559:Tacrolimus